Methotrimeprazine, in doses between 2.5 mg and 12.5 mg per 24 hours (mean 5 mg), was administered by continuous subcutaneous (s.c.) infusion (via syringe driver) in a total of 23 patients with one or more of the following, presumptive, causes of nausea and vomiting: a) drug induced, principally unresponsive to oral and/or s.c. b) metabolic, principally unresponsive to oral and/or s.c. The majority of patients had previously failed to respond to oral cyclizine, metoclopramide and/or prochlorperazine. Only one of the 23 patients (given 12.5 mg per 24 hours) experienced sedation to any degree.
A non-sedating anti-emetic composition in oral unit dosage form comprising from 1 to 5 mg of methotrimeprazine per unit dosage, or in unit dosage form for parenteral administration comprising from 1 to 5 mg of methotrimeprazine in each unit dosage....
For use as an anti-psychotic agent it is recommended by mouth, initially at dosages of 25 to 50 mg daily, increased as necessary to dosages of up to lg daily. In this article the anti-emetic effect of orally administered levomepromacine (methotrimeprazine) administered in two doses of 8 to 15 mg 12 hours and 1 hour before the administration of the cytotoxic agents, i.e.
More recently methotrimeprazine has been prescribed as an adjunctive treatment in terminal care, including the management of pain and associated distress, restlessness or vomiting. at a total dosage of from 16 to 30 mg, is discussed.
Drugs injected directly into the bloodstream act very rapidly but are generally used only in the doctor's office or the emergency room.
Medications for headache are available using all of these routes of administration.